Volitionrx Ltd (VNRX) Stock Price, Quote & News

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progre...

Industry: Medical Devices

Sector: Healthcare

Phone: 646 650 1351

Website: volition.com

Address:

1489 West Warm Springs Road, Suite 110, Henderson, United States

Kululu Apr. 23 at 4:49 PM

$VNRX great stock. Counting days to become zero. I am telling you this will drop 50-70% more post reverse split. Terrible management bunch inf thieves are running this company

2 · Reply

2021er Apr. 23 at 3:54 PM

$VNRX price as well

0 · Reply

moemog Apr. 23 at 2:29 PM

$VNRX again and again and again ⏰

1 · Reply

DARKP00L Apr. 23 at 12:31 PM

$VNRX 08:27 on Apr. 23 2026 VolitionRx Announces Compliance Plan For Continued Listing Accepted By NYSE American #tradeideas

0 · Reply

Kululu Apr. 21 at 3:04 PM

$VNRX the fat ceo is taking us to the wonderland where he will struck all the dubious deals he talked about

0 · Reply

Kululu Apr. 21 at 2:47 PM

$VNRX best stock in the market.

0 · Reply

focafoca99 Apr. 20 at 1:39 PM

$VNRX launched an rNuQ webshop to broaden its product offering.

0 · Reply

SuellenD Apr. 20 at 1:02 PM

$VNRX news out 🚀

1 · Reply

Glencore Apr. 19 at 10:35 AM

$VNRX What percent of the company are actually happy with the managemrnt,at least 98 percent of the shareholders have lost money besides from the management who get most of there shares for free for poor performance.It is definitely time for a change.

1 · Reply

Glencore Apr. 19 at 10:31 AM

$VNRX

0 · Reply

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Apr 20, 2026, 7:30 AM EDT - 5 days ago

Volition Launches rNuQ™ Webshop Broadening Product Range

Apr 1, 2026, 8:30 AM EDT - 24 days ago

VolitionRx Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:05 PM EDT - 25 days ago

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Mar 31, 2026, 8:16 AM EDT - 25 days ago

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Mar 30, 2026, 8:13 AM EDT - 26 days ago

Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

Mar 26, 2026, 8:17 AM EDT - 4 weeks ago

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

Mar 25, 2026, 4:12 PM EDT - 4 weeks ago

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

Mar 25, 2026, 8:17 AM EDT - 4 weeks ago

Volition Announces Detection of Over 95% of Early-Stage Cancers

Mar 18, 2026, 8:17 AM EDT - 5 weeks ago

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

Mar 6, 2026, 8:10 AM EST - 7 weeks ago

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Feb 25, 2026, 8:10 AM EST - 2 months ago

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

Feb 10, 2026, 8:07 AM EST - 2 months ago

Volition Announces the Appointment of New Distributor for Nu.Q® Discover

Feb 9, 2026, 5:20 PM EST - 2 months ago

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 4, 2026, 8:45 AM EST - 2 months ago

Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

Jan 30, 2026, 8:50 AM EST - 3 months ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Jan 27, 2026, 8:00 AM EST - 3 months ago

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

Jan 20, 2026, 8:25 AM EST - 3 months ago

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

Jan 16, 2026, 8:45 AM EST - 3 months ago

Volition Sponsors Symposium at Veterinary Meeting and Expo

Jan 8, 2026, 9:15 AM EST - 3 months ago

VolitionRx Secures $2.0 Million in Funding

Jan 8, 2026, 8:45 AM EST - 3 months ago

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Dec 17, 2025, 8:45 AM EST - 4 months ago

Volition Issues Business Review 2025

Dec 11, 2025, 9:00 AM EST - 4 months ago

Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

Dec 8, 2025, 9:00 AM EST - 4 months ago

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

Dec 4, 2025, 9:00 AM EST - 5 months ago

VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

Nov 25, 2025, 8:45 AM EST - 5 months ago

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

Nov 14, 2025, 8:30 AM EST - 5 months ago

VolitionRx Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:10 PM EST - 5 months ago

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 8:45 AM EST - 5 months ago

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Oct 17, 2025, 8:00 AM EDT - 6 months ago

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

Oct 10, 2025, 8:30 AM EDT - 7 months ago

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 9, 2025, 4:05 PM EDT - 7 months ago

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 8, 2025, 11:00 AM EDT - 7 months ago

VolitionRx Transcript: Status Update

Oct 2, 2025, 8:45 AM EDT - 7 months ago

Volition Sponsors Upcoming GenomeWeb Webinar

Sep 29, 2025, 9:30 AM EDT - 7 months ago

Volition Signs Co-Marketing and Services Agreement with Hologic

HOLX

Sep 9, 2025, 8:45 AM EDT - 8 months ago

Volition Signs First Human Out Licensing Deal

Aug 15, 2025, 8:30 AM EDT - 9 months ago

VolitionRx Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:10 PM EDT - 9 months ago

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

Aug 8, 2025, 8:30 AM EDT - 9 months ago

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

Aug 4, 2025, 4:01 PM EDT - 9 months ago

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Jul 16, 2025, 8:00 AM EDT - 10 months ago

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Jul 8, 2025, 8:00 AM EDT - 10 months ago

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Jun 12, 2025, 8:30 AM EDT - 11 months ago

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Jun 4, 2025, 9:00 PM EDT - 11 months ago

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

May 19, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 16, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Earnings Call Transcript: Q1 2025

May 15, 2025, 5:37 PM EDT - 1 year ago

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 12, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 7, 2025, 8:30 AM EDT - 1 year ago

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

Apr 29, 2025, 8:30 AM EDT - 1 year ago

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Mar 31, 2025, 4:30 PM EDT - 1 year ago

VolitionRx Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:05 PM EDT - 1 year ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Mar 26, 2025, 8:00 AM EDT - 1 year ago

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Mar 25, 2025, 9:30 AM EDT - 1 year ago

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Nov 15, 2024, 8:30 AM EST - 1 year ago

VolitionRx Earnings Call Transcript: Q3 2024

Oct 21, 2024, 10:00 AM EDT - 1 year ago

VolitionRx Transcript: Status Update

Aug 15, 2024, 8:30 AM EDT - 1 year ago

VolitionRx Earnings Call Transcript: Q2 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

VolitionRx Earnings Call Transcript: Q1 2024

Mar 26, 2024, 8:30 AM EDT - 2 years ago

VolitionRx Earnings Call Transcript: Q4 2023

Nov 15, 2023, 8:30 AM EST - 2 years ago

VolitionRx Earnings Call Transcript: Q3 2023

Aug 15, 2023, 8:30 AM EDT - 2 years ago

VolitionRx Earnings Call Transcript: Q2 2023

May 11, 2023, 2:00 PM EDT - 3 years ago

VolitionRx Transcript: CMD 2023

May 11, 2023, 8:30 AM EDT - 3 years ago

VolitionRx Earnings Call Transcript: Q1 2023

Mar 16, 2023, 8:30 AM EDT - 3 years ago

VolitionRx Earnings Call Transcript: Q4 2022

Kululu Apr. 23 at 4:49 PM

$VNRX great stock. Counting days to become zero. I am telling you this will drop 50-70% more post reverse split. Terrible management bunch inf thieves are running this company

2 · Reply

2021er Apr. 23 at 3:54 PM

$VNRX price as well

0 · Reply

moemog Apr. 23 at 2:29 PM

$VNRX again and again and again ⏰

1 · Reply

DARKP00L Apr. 23 at 12:31 PM

$VNRX 08:27 on Apr. 23 2026 VolitionRx Announces Compliance Plan For Continued Listing Accepted By NYSE American #tradeideas

0 · Reply

Kululu Apr. 21 at 3:04 PM

$VNRX the fat ceo is taking us to the wonderland where he will struck all the dubious deals he talked about

0 · Reply

Kululu Apr. 21 at 2:47 PM

$VNRX best stock in the market.

0 · Reply

focafoca99 Apr. 20 at 1:39 PM

$VNRX launched an rNuQ webshop to broaden its product offering.

0 · Reply

SuellenD Apr. 20 at 1:02 PM

$VNRX news out 🚀

1 · Reply

Glencore Apr. 19 at 10:35 AM

1 · Reply

Glencore Apr. 19 at 10:31 AM

$VNRX

0 · Reply

2021er Apr. 18 at 7:56 AM

$VNRX

0 · Reply

Samuelstark Apr. 17 at 9:33 PM

$VNRX Damn.

0 · Reply

Raziel66 Apr. 17 at 9:29 PM

$VNRX stock split 1 for 20 and effective day is 28th April

0 · Reply

Kululu Apr. 17 at 9:19 PM

$VNRX ultimately it will come below 10 Cents per share post adjusted basis. Kudos to ten company for robbing people in daylight

0 · Reply

STMZ Apr. 17 at 9:17 PM

$VNRX

0 · Reply

Kululu Apr. 17 at 9:13 PM

$VNRX here you go. You always expect the worse form this stock. Here comes the reverse split.

0 · Reply

Kululu Apr. 16 at 4:39 PM

$VNRX that fat ceo still working on deals with ten liquid biopsy companies. He has been negotiating with them for past one year. The deals will be finalized when the humanity will come to its end. He will make these deals available for zombies

1 · Reply

Samuelstark Apr. 16 at 2:00 PM

$VNRX

0 · Reply

STMZ Apr. 15 at 7:24 PM

$VNRX

0 · Reply

Samuelstark Apr. 15 at 2:04 PM

$VNRX 👀

0 · Reply

moemog Apr. 15 at 12:47 AM

$VNRX 💣

0 · Reply

Kululu Apr. 13 at 6:02 PM

$VNRX I think cunts in the management wants the stock to fall. They can earn money by short selling and diluting. Plus they want to keep under 20 cent as they want to implement a rs. Bunch of cheaters

0 · Reply

Market Cap	22.82M
Revenue (ttm)	1.73M
Net Income (ttm)	-23.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,350.29%
Debt to Equity Ratio	-0.26

Volume	1,767,000
Avg Vol	13,316,670
Day's Range	N/A - N/A
Shares Out	158.48M
Stochastic %K	11%
Beta	1.33
Analysts	Strong Sell
Price Target	$1.70